Medicare | Association for Accessible Medicines

Seniors Pay More for Generic Medicines Every Year While Prices Continue to Fall. Why?

Avalere analysis finds Part D prescription drug plans continue to increase patient copays for generics by moving them to higher tiers

WASHINGTON (April 17, 2024) — The Association for Accessible Medicines, the leading trade association for generic and biosimilar manufacturers, commented on an analysis released yesterday by Avalere showing that Medicare plans increase patient costs for generic medicines by moving thos

Read more about Seniors Pay More for Generic Medicines Every Year While Prices Continue to Fall. Why?

Seniors Pay More for Generic Medicines Every Year While Prices Continue to Fall. Why?

Last month, as part of its Fiscal Year 2025 budget, the Biden Administration proposed a new initiative under the Medicare Part D program to require all Part D plans to offer a standard list of generic drugs with a maximum copayment of $2 per 30-day supply.

Read more about Seniors Pay More for Generic Medicines Every Year While Prices Continue to Fall. Why?

AAM Statement on President Biden's Budget Plan

WASHINGTON, D.C. (March 7, 2023) – The Association for Accessible Medicines Interim CEO, David Gaugh, today released the following statement regarding President Biden's budget plan.

Read more about AAM Statement on President Biden's Budget Plan

AAM Applauds CMS for Requiring Health Plans to Place Generic Drugs On Generic Tiers

WASHINGTON, DC (January 30, 2023) — The Association for Accessible Medicines (AAM) applauds the Centers for Medicare & Medicaid Services (CMS) for several of the recommended provisions outlined in the proposed Patient Protection and Affordable Care Act, HHS Notice of Benefit and Payment Parameters for 2024. In particular, AAM publicly commends the administration’s efforts to standardize plan choice by requiring generic drugs be placed on “generic” tiers and brand-name drugs on “brand-name” tiers.

Read more about AAM Applauds CMS for Requiring Health Plans to Place Generic Drugs On Generic Tiers

Patients Pay More When Generic Drugs Are Placed On Non-Generic Tiers, Even Though Prices For Generics Are Going Down

Numerous studies agree: Generics provide savings on prescription drugs. And six years into a sustained period of price deflation, many generic prices are lower than ever. But inexplicably, patients are paying more for many generics. Although the Medicare program has rules to safeguard beneficiaries, it has allowed Medicare drug plans to make changes that require patients to pay more for many generic drugs even as the prices of those drugs have fallen.

Read more about Patients Pay More When Generic Drugs Are Placed On Non-Generic Tiers, Even Though Prices For Generics Are Going Down

AAM Statement on the Centers for Medicare & Medicaid Services’ Implementation of Medicare Part B Payment Changes for Biosimilars

WASHINGTON D.C. (October 3, 2022) — The Association for Accessible Medicines (AAM) and its Biosimilars Council applaud the Centers for Medicare & Medicaid Services for its support of biosimilars and rapid implementation of the enhanced payment for biosimilars in Medicare Part B.

Read more about AAM Statement on the Centers for Medicare & Medicaid Services’ Implementation of Medicare Part B Payment Changes for Biosimilars

Generic and Biosimilar Drugs Generate A Record $373 Billion For America’s Patients and Healthcare System in 2021

Despite Savings from Generic Drugs, Many Patients Continue to Pay More than Necessary

WASHINGTON, DC (September 21, 2022) — Today, the Association for Accessible Medicines (AAM), the leading trade association for generic and biosimilar manufacturers, released its 2022 U.S. Generic & Biosimilar Medicines Savings Report highlighting the value of generic and biosimilar medicines.

Read more about Generic and Biosimilar Drugs Generate A Record $373 Billion For America’s Patients and Healthcare System in 2021

Report: 2022 U.S. Generic and Biosimilar Medicines Savings Report

Featuring data from IQVIA, the 2022 U.S. Generic and Biosimilar Medicines Savings Report reveals generic and biosimilar drugs generated a record $373 billion for America’s patients and healthcare system in 2021. Despite the tremendous savings from generic drugs, many patients continue to pay more than necessary.

Read more about Report: 2022 U.S. Generic and Biosimilar Medicines Savings Report

Drug Price Negotiation Proposals Undermine Current Bipartisan Approaches to Lower Drug Spending

Congress is actively seeking to advance legislation to allow the Medicare program to “negotiate” the prices of brand drugs. However, these proposals neglect to consider the impact on the development of lower-cost generic and biosimilar medicines.

Read more about Drug Price Negotiation Proposals Undermine Current Bipartisan Approaches to Lower Drug Spending

Medicare Negotiations Serve as a Catalyst to a Perpetual Monopoly

Generic medicines offer proven cost savings for America’s seniors and taxpayers, more than $2 trillion over the past 10 years alone. This is the result of robust head-to-head price competition under which multiple generic drug makers fight for market share based on dramatically lower prices.

Read more about Medicare Negotiations Serve as a Catalyst to a Perpetual Monopoly

Subscribe to Medicare